Abat, S.S.AbatAbd Rahman, R.R.Abd RahmanAbdul Cader, R.R.Abdul CaderAbdul Hafidz, M. I.M. I.Abdul HafidzAbdul Wahab, M. Z.M. Z.Abdul WahabAbdullah, N. K.N. K.AbdullahAbdul-Samad, T.T.Abdul-SamadAbe, M.M.AbeAbraham, N.N.AbrahamAcheampong, S.S.AcheampongAchiri, P.P.AchiriYI-DER JIANGCheng, HTHTChengFENG-JUNG YANG etc.Acosta, J. A.J. A.AcostaAdeleke, A.A.AdelekeAdell, V.V.AdellAdewuyi-Dalton, R.R.Adewuyi-DaltonAdnan, N.N.AdnanAfricano, A.A.AfricanoAgharazii, M.M.AgharaziiAguilar, F.F.AguilarAguilera, A.A.AguileraAhmad, M.M.AhmadAhmad, M. K.M. K.AhmadAhmad, N. A.N. A.AhmadAhmad, N. H.N. H.AhmadAhmad, N. I.N. I.AhmadAhmad Miswan, N.N.Ahmad MiswanAhmad Rosdi, H.H.Ahmad RosdiAhmed, I.I.AhmedAhmed, S.S.AhmedAiello, J.J.AielloAitken, A.A.AitkenAitSadi, R.R.AitSadiAker, S.S.AkerAkimoto, S.S.AkimotoAkinfolarin, A.A.AkinfolarinAkram, S.S.AkramAlberici, F.F.AlbericiAlbert, C.C.AlbertAldrich, L.L.AldrichAlegata, M.M.AlegataAlexander, L.L.AlexanderAlfaress, S.S.AlfaressAlhadj Ali, M.M.Alhadj AliAli, A.A.AliAlicic, R.R.AlicicAliu, A.A.AliuAlmaraz, R.R.AlmarazAlmasarwah, R.R.AlmasarwahAlmeida, J.J.AlmeidaAloisi, A.A.AloisiAl-Rabadi, L.L.Al-RabadiAlscher, D.D.AlscherAlvarez, P.P.AlvarezAl-Zeer, B.B.Al-ZeerAmat, M.M.AmatAmbrose, C.C.AmbroseAmmar, H.H.AmmarAn, Y.Y.AnAndriaccio, L.L.AndriaccioAnsu, K.K.AnsuApostolidi, A.A.ApostolidiArai, N.N.AraiAraki, H.H.ArakiAraki, S.S.ArakiArbi, A.A.ArbiArechiga, O.O.ArechigaArmstrong, S.S.ArmstrongArnold, T.T.ArnoldAronoff, S.S.AronoffArriaga, W.W.ArriagaArroyo, J.J.ArroyoArteaga, D.D.ArteagaAsahara, S.S.AsaharaAsai, A.A.AsaiAsai, N.N.AsaiAsano, S.S.AsanoAsawa, M.M.AsawaAsmee, M. F.M. F.AsmeeAucella, F.F.AucellaAugustin, M.M.AugustinAvery, A.A.AveryAwad, A.A.AwadAwang, I. Y.I. Y.AwangAwazawa, M.M.AwazawaAxler, A.A.AxlerAyub, W.W.AyubAzhari, Z.Z.AzhariBaccaro, R.R.BaccaroBadin, C.C.BadinBagwell, B.B.BagwellBahlmann-Kroll, E.E.Bahlmann-KrollBahtar, A. Z.A. Z.BahtarBaigent, C.C.BaigentBains, D.D.BainsBajaj, H.H.BajajBaker, R.R.BakerBaldini, E.E.BaldiniBanas, B.B.BanasBanerjee, D.D.BanerjeeBanno, S.S.Banno2024-03-112024-03-112024-0122138587https://scholars.lib.ntu.edu.tw/handle/123456789/640731The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population.en[SDGs]SDG3journal article10.1016/S2213-8587(23)00322-4380613722-s2.0-85179107702https://api.elsevier.com/content/abstract/scopus_id/85179107702